Press Releases

Sevion Therapeutics Presents Cow Antibody Platform at PEGS 2015
« back

SAN DIEGO, CA – May 4, 2015 – Sevion Therapeutics, Inc. (“Sevion” or the “Company”)(OTCBB: SVON), a biopharmaceutical company which discovers, develops and acquires next-generation biologics for the treatment of cancer and immunological diseases, today announced that Dr. Vaughn Smider, MD, PhD, Chief Scientific Officer, gave an oral presentation on the company’s cow-derived ultralong CDR3 antibody platform and an update on SVN-001, its antibody targeting the ion channel Kv1.3 for autoimmune diseases, at the international PEGS conference in Boston, MA on May 4, 2015.  “The unique ultralong CDR3s of cow antibodies provide a new domain for which to target traditionally difficult and high value antigens, and we are eager to share our discoveries and progress with the protein therapeutics community at PEGS 2015”, noted Dr. Smider.  The unique structure and genetic diversity mechanisms of cows were featured on the cover of Cell in 2013, and the company has since developed discovery and commercialization strategies based on the novel cow antibody scaffold. About Sevion Therapeutics  Sevion Therapeutics is a biopharmaceutical company building and developing a portfolio of innovative therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company’s product candidates are derived from multiple key proprietary technology platforms: cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. Sevion has leveraged these technologies to build a pipeline of innovative product candidates. For more information, please visit SevionTherapeutics.com. Forward-Looking Statements Certain statements included in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from such statements expressed or implied herein as a result of a variety of factors, including, but not limited to: the Company’s ability to integrate the Fabrus science and operations, including the rebranding of the Company as Sevion Therapeutics; the Company’s ability to continue as a going concern; the ability of the Company to consummate additional financings; the development of the Company’s gene and antibody technology; the approval of the Company’s patent applications; the current uncertainty in the patent landscape surrounding small inhibitory RNA and the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products; the timing and success of the Company’s preliminary studies, preclinical research and clinical trials; competition and the timing of projects and trends in future operating performance; and the quotation of the Company’s common stock on an over-the-counter securities market, as well as other factors expressed from time to time in the Company’s periodic filings with the Securities and Exchange Commission (the “SEC”). As a result, this press release should be read in conjunction with the Company’s periodic filings with the SEC. The forward-looking statements contained herein are made only as of the date of this press release, and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.   For investors contact:   Sevion Therapeutics 858-909-0749